MesoPher is a platform technology. Currently 3 clinical studies are ongoing.



Pleural mesothelioma

Pleural malignant mesothelioma is a cancer of the lining of the lungs. Pleural mesothelioma is caused by inhalation of asbestos fibers. In Western countries about 13.000 mesothelioma deaths are reported annually and this number is increasing.

There is only one therapy approved for the treatment of malignant mesothelioma, a combination chemotherapy of pemetrexed and cisplatin. Median survival with the best standard of care is 12 months after diagnosis. Read more.

Peritoneal mesothelioma

Peritoneal mesothelioma is a cancer of the peritoneum (the lining of the abdominal cavity, approximately 10 % of all mesothelioma cases).

Currently, surgery and chemotherapy are the standard of care. However, recurrence rates are high. Read more.

Pancreatic cancer

REACtiVe (Rotterdam pancrEAtic Cancer Vaccination trial) is an open label phase II study in adult patients with surgically resected pancreatic cancer who have received adjuvant standard of care treatment. Read more.